Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Johnson & Johnson Medical Devices, Franchise Health Economics & Market Access, Irvine, CA, USA.
J Comp Eff Res. 2020 Apr;9(5):375-385. doi: 10.2217/cer-2019-0156. Epub 2020 Mar 5.
To compare outcomes among patients with implantable cardioverter defibrillator/cardiac resynchronization therapy-defibrillator undergoing outpatient ventricular tachycardia (VT) catheter ablation using intracardiac echocardiography (ICE) versus no ICE. Patients were classified into ICE (n = 1143)/non-ICE (n = 1677) groups based on ICE procedure codes. Patients in each group were propensity matched on study covariates. Survival analyses were used to assess outcomes. To examine residual confounding, falsification outcomes were evaluated. ICE patients had a 24% lower risk of all-cause readmissions, 24% lower risk of cardiovascular-related and 20% lower risk of VT-related readmissions compared with non-ICE patients. Falsification analyses for ICE use association were nonsignificant. Patients with implantable cardioverter defibrillator/cardiac resynchronization therapy-defibrillator undergoing VT ablation with ICE use had significantly lower likelihood of VT-related readmission.
比较使用心腔内超声心动图(ICE)与不使用 ICE 对植入式心脏复律除颤器/心脏再同步治疗除颤器患者进行门诊室性心动过速(VT)导管消融的治疗效果。根据 ICE 手术编码,患者分为 ICE(n=1143)/非 ICE(n=1677)组。对每组患者进行研究协变量的倾向匹配。采用生存分析评估结果。为了检查残余混杂因素,评估了虚假结局。与非 ICE 患者相比,ICE 患者全因再入院风险降低 24%,心血管相关再入院风险降低 24%,VT 相关再入院风险降低 20%。ICE 使用关联的虚假分析无显著意义。与未使用 ICE 的患者相比,使用 ICE 的植入式心脏复律除颤器/心脏再同步治疗除颤器患者 VT 相关再入院的可能性显著降低。